Sami-Sabinsa Group founder Dr. Muhammed Majeed was lead author of a paper published on the cumulative safety data of ForsLean®, the company’s patented coleus forskohlii extract. Investigation of Acute, SubAcute, Chronic Oral Toxicity and Mutagenicity of Coleus forskohlii Briq. Hydroethanolic Extract was published in the International Journal Of Pharmacy & Pharmaceutical Research December 2015 Vol.:5, Issue:1.The Paper concludes that there were no signs of toxicity in the repeated doses of 28 days (acute study) and 180 days (chronic study) with Coleus forskohlii (containing 10% forskolin). The repeated oral exposure to this extract up to 1000 mg/kg/day does not produce any toxic effects, hence considered to have ‘No Observed Adverse Effect Level’ (NOAEL) under the test conditions employed.
Furthermore, ForsLean® exhibited a nonmutagenic response, thereby, showing it to be devoid of adverse effect on DNA of the organism.
“Coleus forskohlii root is a well established ingredient with a long history of safety. Even for such well known herbs though, additions to the scientific literature are always welcome and this article serves to increase our understanding of the appropriate use of this important herb and its extracts,” said American Herbal Products Association President Michael McGuffin.
Sabinsa / Sami holds multiple patents on ForsLean® internationally, including in the US, Canada, and the European Union. The company has an extensive cultivation program of coleus plants to insure a continuous supply of high quality raw material.
“While Sabinsa continues to innovate new efficacious ingredients, we are also committed to delivering the safest ingredients possible,” said Shaheen Majeed, Sabinsa’s Marketing Director. “Our award winning ForsLean® brand is set apart from other suppliers of Coleus forskohlii with our safety publications, patents, and human clinical studies. Substitutions just don’t have those advantages.”
International Journal of Pharmacy and Pharmaceutical Research (www.ijppr.humanjournals.com) is an open access, peer reviewed international monthly journal dedicated to the latest advancement in Pharmacy and Pharmaceutical Research. The Journal and Editorial Board endeavor to attract and publish articles from a variety of disciplines and educational settings to promote excellence in pharmaceutical research.
About Sabinsa Corporation:
Sabinsa’s mission is to provide alternative and complementary natural products for human nutrition and wellbeing. Over the past 27 years, Sabinsa has brought to market more than 100 standardized botanical extracts, and privately funded clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 fulltime scientists conducting ongoing research in India and the United States, Sabinsa and parent company Sami Labs Ltd. continue to develop, patent and manufacture phytonutrients for the world market, with ingredients that are both Halal and Kosher.
For more information, visit www.sabinsa.com.